-+ 0.00%
-+ 0.00%
-+ 0.00%

20/20 BioLabs Q3 net loss widens 67% year over year to $1.38 million; Q3 revenue falls 9% to $380,216

PUBT·11/16/2026 21:08:44
Listen to the news
20/20 BioLabs Q3 net loss widens 67% year over year to $1.38 million; Q3 revenue falls 9% to $380,216
  • 20/20 BioLabs’ third-quarter 2026 net loss widened 67% year over year to $1.38 million.
  • Revenue fell 9% year over year to $380,216, reflecting the timing of state-funded firefighter cancer screening programs.
  • Cash totaled $3.63 million at September 30, 2026, with no outstanding borrowings.
  • Vermont executed a two-year firefighter screening contract, with testing expected to contribute revenue in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 20/20 Biolabs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161605PRIMZONEFULLFEED9878777) on November 16, 2026, and is solely responsible for the information contained therein.